Zsolt Harsanyi - 01 Jun 2022 Form 4 Insider Report for Aptevo Therapeutics Inc. (APVO)

Role
Director
Signature
SoYoung Kwon, Attorney-in-Fact
Issuer symbol
APVO
Transactions as of
01 Jun 2022
Net transactions value
$0
Form type
4
Filing time
03 Jun 2022, 15:10:12 UTC
Previous filing
31 May 2022
Next filing
10 Aug 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APVO Common Stock Options Exercise +298 +6.9% 4,607 01 Jun 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APVO Restricted Stock Unit Options Exercise $0 -298 -33% $0.000000 595 01 Jun 2022 Common Stock 298 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
F2 Shares beneficially owned by the reporting person were adjusted to include the following shares of the Issuer's common stock: (i) 210 shares that were inadvertently omitted from the Form 4 filed on August 5, 2016; and (ii) 527 shares that were originally disclosed in the Form 4 filed on August 5, 2016, but due to a mathematical error, were not included in the aggregate number of shares beneficially owned in the Form 4 filed on June 7, 2019. In each of subsections (i) and (ii) above, the number of shares were adjusted to reflect a 1-for-14 reverse stock split of the Issuer's common stock effective as of March 26, 2020.
F3 On June 1, 2021, the reporting person was granted 893 RSUs, vesting in three approximately equal annual installments beginning on June 1, 2022.